RUA Life Sciences PLC Directorate Changes (6524G)
March 31 2022 - 1:01AM
UK Regulatory
TIDMRUA
RNS Number : 6524G
RUA Life Sciences PLC
31 March 2022
31 March 2022
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Directorate Changes
Further to its announcement of 16 December 2021, RUA Life
Sciences, the holding company of a group of medical device
businesses focused on the exploitation of the world's leading
long-term implantable biostable polymer (Elast-Eon(TM) ), is
pleased to announce the appointments, with immediate effect, to the
Board of Lachlan Smith as Chief Financial Officer, and Dr Iain
Anthony as Director of Clinical and Regulatory Affairs.
Iain joined the Company in November 2021 as Director of Clinical
and Regulatory Affairs and brings a wealth of relevant
cardiovascular medical device experience to the Company. He has
over 15 years' experience in the medical device industry in both
commercial and NHS settings. He was recruited from the Swiss based
MedAlliance where he was Director of Pre-Clinical/Clinical
Regulatory Affairs focusing on development and approval of drug
coated coronary and peripheral angioplasty balloons. Prior to this,
Iain was Head of Clinical Affairs at Terumo Aortic where he
developed his knowledge and experience of the global vascular graft
business.
Lachlan joined the Company in December 2021 as Chief Financial
Officer and is a Fellow of the Association of Chartered Certified
Accountants. With 20 years' experience in accounting and financial
management and digital transformation, the last 14 years of which
were spent in strategic leadership roles at high growth businesses.
Prior to joining RUA Life Sciences, Lachlan served as Finance
Director at technology companies Silver Cloud Smarter Technology
and Equator.
Since their respective appointments, both Iain and Lachlan have
been playing key roles in the business providing the expertise to
lead the revised regulatory strategy and the detailed financial
planning to maximise contribution from the vascular graft range by
prioritising both manufacturing efforts and sales focus.
Further information in accordance with paragraph (g) of Schedule
Two of the AIM Rules for Companies is set out at the end of this
announcement.
Caroline Stretton, Group Managing Director of the Company,
commented : "The Board appointments of Iain and Lachlan will ensure
that we have the right management expertise to support the growth
of the Group and enable the vascular graft business to accelerate
its clinical study plans for earlier entry into global
markets."
Bill Brown, Chairman of the Company, commented: "I am delighted
to be welcoming two new members to our Board who bring with them a
great deal of knowledge and expertise and look forward to working
with them in the coming years."
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Caroline Stretton, Group Managing Director Tel: +44 (0)1294 317073
Shore Capital (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7408 4080
Tom Griffiths/David Coaten
Cenkos Securities plc (Joint Broker) Tel: +44 (0)20 7397 8900
Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
enabling medical devices with Elast-Eon(TM) , the world's leading
long-term implantable polyurethane. Whether it is licensing
Elast-Eon(TM) , manufacturing a device or component, or developing
next generation medical devices, a RUA Life Sciences business is
pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 8
million implants and 15 years of successful clinical use, RUA's
polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Medical: End-to-end contract developer and manufacturer
of medical devices and implantable fabric specialist.
RUA Biomaterials: Licensor of Elast-Eon(TM) polymers to the medical
device industry.
RUA Vascular: Development of polymer sealed grafts and soft
tissue patches.
RUA Structural Heart: Development of tri leaflet polymeric heart
valves.
INFORMATION REQUIRED UNDER SCHEDULE TWO, PARAGRAPH (G) OF
THE AIM RULES FOR COMPANIES ("AIM RULES")
Full name: Lachlan Arthur Smith
Age 41
RUA Life Sciences plc ordinary
shares held: 0
Current directorships: Ornum Technology Limited
Historic directorships (within
previous 5 years): Baron Knight Limited
Laird Logistics Limited
Scottish Target Shooting
Silver Cloud Smarter Technology
Limited
Full name: Iain Crawford Anthony
Age 46
RUA Life Sciences plc ordinary
shares held: 0
Current directorships and/or historic
directorships (within previous
5 years): None
There is no further information to be disclosed in relation
to the appointments of either Lachlan Smith or Iain Anthony
pursuant to Schedule Two, paragraph (g) of the AIM Rules.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABUGDXXXXDGDG
(END) Dow Jones Newswires
March 31, 2022 02:01 ET (06:01 GMT)
Aortech (LSE:AOR)
Historical Stock Chart
From Apr 2024 to May 2024
Aortech (LSE:AOR)
Historical Stock Chart
From May 2023 to May 2024